Nashville TN 白血病临床试验
12项针对 白血病的研究正在 Nashville及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本(英文)
正在为研究招募参与者?将此页面置顶展示 — $99 / 30天 →
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
招募中3 期
- Quetzal Site 12, Nashville
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
招募中1/2 期
- Sarah Cannon Research Institute, Nashville
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
招募中3 期
- Tennessee Oncology, Nashville
- TriStar Centennial Medical Center, Nashville
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
招募中1 期
- Vanderbilt University Medical Center, Nashville
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
招募中1/2 期
- TriStar BMT, Nashville
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
招募中2 期
- Vanderbilt University, Ingram Cancer Center, Nashville
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
招募中2/3 期
- Vanderbilt University Medical Center, Nashville
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
招募中1 期
- TriStar Bone Marrow Transplant, Nashville
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
招募中观察性研究欢迎健康志愿者
- Vanderbilt-Ingram Cancer Center, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中观察性研究
- Massive Bio SYNERGY-AI site, Nashville
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
招募中1 期
- Sarah Cannon Research Institute, Nashville
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
招募中1 期
- TriStar Bone Marrow Transplant, Nashville
其他城市的 白血病试验
- Houston, TX28 项研究
- Boston, MA25 项研究
- New York City, NY19 项研究
- Los Angeles, CA16 项研究
- Chicago, IL16 项研究
- Durham, NC13 项研究
- Columbus, OH12 项研究
- Philadelphia, PA12 项研究
- Baldwin Park, CA12 项研究
- Milwaukee, WI11 项研究
- Seattle, WA11 项研究
- Atlanta, GA11 项研究
Nashville的其他研究
- 非小细胞肺癌97 项研究
- 乳腺癌81 项研究
- 转移性癌症70 项研究
- 结直肠癌69 项研究
- 癌症(所有类型)65 项研究
- 卵巢癌49 项研究
- 前列腺癌43 项研究
- 肺癌40 项研究
- 头颈鳞状细胞癌39 项研究
- 胰腺癌39 项研究
- 子宫内膜癌38 项研究
- 黑色素瘤33 项研究
数据来自 ClinicalTrials.gov,检索日期:2026年10月6日。每项研究自行设定入选标准,由研究团队决定谁能参与。